Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Alimera Sciences, Inc.
Alimera Sciences, Inc. News
Alimera Sciences, Inc. Quantitative Score
About Alimera Sciences, Inc.
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Alimera Sciences, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Alimera Sciences, Inc. Financials
Table Compare
Compare ALIM metrics with: | |||
|---|---|---|---|
Earnings & Growth | ALIM | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ALIM | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ALIM | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ALIM | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Alimera Sciences, Inc. Income
Alimera Sciences, Inc. Balance Sheet
Alimera Sciences, Inc. Cash Flow
Alimera Sciences, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Alimera Sciences, Inc. Executives
| Name | Role |
|---|---|
| Mr. Richard S. Eiswirth Jr. | Chief Executive Officer & Director |
| Dr. Philip Ashman Ph.D. | President of International Operations |
| Mr. David R. Holland | Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications & Managed Markets |
| Mr. Jason Werner | Chief Operating Officer |
| Dr. David Dyer M.D. | Chief Retina Specialist |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Richard S. Eiswirth Jr. | Chief Executive Officer & Director | Male | 1968 | 949.27K |
| Dr. Philip Ashman Ph.D. | President of International Operations | 1965 | 516.98K | |
| Mr. David R. Holland | Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications & Managed Markets | Male | 1964 | 413.5K |
| Mr. Jason Werner | Chief Operating Officer | Male | 1978 | 225.66K |
| Dr. David Dyer M.D. | Chief Retina Specialist | -- |
Alimera Sciences, Inc. Insider Trades
| Date | 16 Sep |
| Name | Maltz Elliot |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 75000 |
| Date | 16 Sep |
| Name | Maltz Elliot |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 75000 |
| Date | 16 Sep |
| Name | Maltz Elliot |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 75000 |
| Date | 16 Sep |
| Name | Kaseta Michael |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 50000 |
| Date | 16 Sep |
| Name | Kaseta Michael |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1825 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 Sep | Maltz Elliot | Chief Financial Officer | Disposed | D-Return | 75000 |
| 16 Sep | Maltz Elliot | Chief Financial Officer | Disposed | D-Return | 75000 |
| 16 Sep | Maltz Elliot | Chief Financial Officer | Disposed | D-Return | 75000 |
| 16 Sep | Kaseta Michael | Director | Disposed | D-Return | 50000 |
| 16 Sep | Kaseta Michael | Director | Disposed | D-Return | 1825 |